Protagonist Therapeutics (PTGX)

7.09 -0.25 (3.41%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (6/4/18 *Est.)
- Conference (6/20/2018)

Latest Headlines

Protagonist Therapeutics (PTGX) Reports Phase 1 & Pre-clinical Data on Hepcidin Mimetic PTG-300 June 18, 2018 7:01 AM - StreetInsider Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting June 18, 2018 7:00 AM - PR NewsWire Form 4 Protagonist Therapeutics For: May 29 Filed by: Williams Lewis T June 12, 2018 6:56 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 29 Filed by: Waddill William D. June 12, 2018 6:52 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 29 Filed by: Shanafelt Armen June 12, 2018 6:51 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 29 Filed by: SELICK HAROLD E June 12, 2018 6:49 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 29 Filed by: Noonberg Sarah B. June 12, 2018 6:43 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 29 Filed by: KHOSLA CHAITAN PHD June 12, 2018 6:41 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 29 Filed by: Giraudo Bryan June 12, 2018 6:39 PM - SEC Filing Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference June 6, 2018 7:00 AM - PR NewsWire Barclays Downgrades Protagonist Therapeutics (PTGX) to Equalweight June 6, 2018 5:20 AM - StreetInsider Protagonist Therapeutics Reports Granting of Inducement Award June 1, 2018 7:00 AM - PR NewsWire Form 4 Protagonist Therapeutics For: May 31 Filed by: Saks Samuel R May 31, 2018 6:29 PM - SEC Filing Form 3 Protagonist Therapeutics For: May 21 Filed by: Saks Samuel R May 31, 2018 6:14 PM - SEC Filing Form 8-K Protagonist Therapeutics For: May 29 May 31, 2018 5:07 PM - SEC Filing Form S-8 Protagonist Therapeutics May 30, 2018 5:30 PM - SEC Filing Form SC 13G Protagonist Therapeutics Filed by: BIOTECHNOLOGY VALUE FUND L P May 24, 2018 4:48 PM - SEC Filing Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer May 24, 2018 4:30 PM - PR NewsWire Form 4 Protagonist Therapeutics For: May 17 Filed by: Canaan Partners X LLC May 21, 2018 4:38 PM - SEC Filing Form 4 Protagonist Therapeutics For: May 15 Filed by: Giraudo Bryan May 17, 2018 5:48 PM - SEC Filing Form 3 Protagonist Therapeutics For: May 15 Filed by: Giraudo Bryan May 17, 2018 5:44 PM - SEC Filing Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association May 17, 2018 10:14 AM - PR NewsWire Form 4 Protagonist Therapeutics For: May 14 Filed by: Canaan Partners X LLC May 16, 2018 5:17 PM - SEC Filing Form DEFA14A Protagonist Therapeutics May 16, 2018 8:08 AM - SEC Filing Protagonist Therapeutics (PTGX) Names Bryan Giraudo to Board May 16, 2018 8:08 AM - StreetInsider Form 8-K Protagonist Therapeutics For: May 15 May 16, 2018 8:06 AM - SEC Filing Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors May 16, 2018 8:01 AM - PR NewsWire Form 4 Protagonist Therapeutics For: May 10 Filed by: PATEL DINESH V PH D May 11, 2018 6:51 PM - SEC Filing Form 10-Q Protagonist Therapeutics For: Mar 31 May 9, 2018 4:52 PM - SEC Filing Form 8-K Protagonist Therapeutics For: May 09 May 9, 2018 4:28 PM - SEC Filing Protagonist Therapeutics Reports First Quarter 2018 Financial Results May 9, 2018 4:02 PM - PR NewsWire Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference May 3, 2018 8:01 AM - PR NewsWire Form DEFA14A Protagonist Therapeutics April 18, 2018 4:15 PM - SEC Filing Form DEF 14A Protagonist Therapeutics For: May 29 April 18, 2018 4:06 PM - SEC Filing Form 4 Protagonist Therapeutics For: Apr 02 Filed by: PATEL DINESH V PH D April 3, 2018 5:25 PM - SEC Filing Form 4 Protagonist Therapeutics For: Mar 26 Filed by: PATEL DINESH V PH D March 28, 2018 5:21 PM - SEC Filing Protagonist Therapeutics (PTGX) PT Lowered to $14 at BTIG March 27, 2018 2:07 AM - StreetInsider Protagonist Therapeutics (PTGX) PT Lowered to $13 at Leerink Partners March 27, 2018 1:33 AM - StreetInsider Form 4 Canaan Partners X LLC For: Mar 23 Filed by: Protagonist Therapeutics, Inc March 26, 2018 4:26 PM - SEC Filing Stifel Downgrades Protagonist Therapeutics (PTGX) to Hold Following Removal of PTG-100 From Model March 26, 2018 1:49 PM - StreetInsider Protagonist Therapeutics (PTGX) PT Lowered to $13 at BMO Capital March 26, 2018 10:22 AM - StreetInsider Pre-Open Movers 03/26: (DRIO) (FINL) (USG) Higher; (PTGX) (BHVN) (NBEV) Lower (more...) March 26, 2018 9:13 AM - StreetInsider Form 8-K Protagonist Therapeutics For: Mar 26 March 26, 2018 6:49 AM - SEC Filing Protagonist Therapeutics (PTGX) Discontinues Phase 2b PROPEL Trial of PTG-100 for Treatment of UC following Interim Analysis March 26, 2018 6:47 AM - StreetInsider Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis March 26, 2018 6:45 AM - PR NewsWire Form 4 Canaan Partners X LLC For: Mar 20 Filed by: Protagonist Therapeutics, Inc March 22, 2018 5:33 PM - SEC Filing Full Article List